Hoth Therapeutics Enters Exclusive Patent
License Agreement with VA and Emory
University
Hoth Also Expands Its' Intellectual
Property to Further Its' Market Opportunity for HT-001
NEW
YORK, Dec. 26, 2024 /PRNewswire/ -- Hoth
Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company
focused on developing innovative therapies, today announced that it
has entered into an exclusive patent license agreement with the
U.S. Department of Veterans Affairs (VA). This agreement provides
Hoth with exclusive rights to a jointly owned patent portfolio
co-developed by the VA and Emory
University.
The licensed technology centers on "Glial Cell Line-Derived
Neurotrophic Factor, Obesity, and Obesity-Related Diseases and
Conditions," a groundbreaking innovation aimed at addressing
critical challenges in treating obesity and associated health
conditions. This agreement underscores Hoth Therapeutics'
commitment to advancing transformative healthcare solutions.
Under the terms of the agreement, Hoth Therapeutics will have
exclusive rights to develop, market, and commercialize products and
processes derived from the licensed patents. The VA and
Emory University have granted Hoth this
license to further develop the technology with the goal of ensuring
the benefits of this innovation are accessible to the widest
audience possible.
"We are honored to collaborate with the VA and Emory University to bring this cutting-edge
technology to market," said Robb
Knie, Chief Executive Officer of Hoth Therapeutics. "This
partnership represents a significant milestone in our efforts to
address obesity and related health conditions with innovative,
science-driven solutions. We look forward to advancing this
critical work to improve the lives of patients worldwide."
The agreement includes a comprehensive development plan,
ensuring the continued progress of this technology from the
research phase through commercialization. Hoth Therapeutics plans
to leverage its expertise and resources to bring the licensed
products to the point of practical application while adhering to
rigorous development benchmarks.
This collaboration exemplifies Hoth's dedication to fostering
partnerships that advance scientific discoveries into therapeutic
solutions. The company remains steadfast in its mission to improve
patient outcomes and address unmet medical needs.
Hoth has also entered into an agreement to further protect its
intellectual property by signing an LOI to acquire additional
provisional patent protection for its lead therapeutic HT-001. The
additional intellectual property expands HT-001's reach to other
cancer therapeutics.
About Hoth Therapeutics, Inc.
Hoth Therapeutics is a clinical-stage biopharmaceutical company
dedicated to developing innovative, impactful, and
ground-breaking treatments with a goal to improve patient
quality of life. We are a catalyst in early-stage
pharmaceutical research and development, elevating drugs from
the bench to pre-clinical and clinical testing. Utilizing a
patient-centric approach, we collaborate and partner with a
team of scientists, clinicians, and key opinion leaders to
seek out and investigate therapeutics that hold immense
potential to create breakthroughs and diversify treatment
options. To learn more, please visit
https://ir.hoththerapeutics.com/.
Forward-Looking Statement
This press release includes
forward-looking statements based
upon Hoth's current expectations, which may
constitute forward-looking statements for the purposes of the safe
harbor provisions under the Private Securities Litigation Reform
Act of 1995 and other federal securities laws, and are subject to
substantial risks, uncertainties, and assumptions. These statements
concern Hoth's business strategies; the timing of regulatory
submissions; the ability to obtain and maintain regulatory approval
of existing product
candidates and any other product
candidates we may develop, and the labeling
under any approval we may
obtain; the timing and costs of clinical trials,
and the timing
and costs of other expenses; market acceptance
of our products; the ultimate impact
of any health epidemic, on our business, our
clinical trials, our research programs, healthcare systems, or the
global economy as a whole; our intellectual property; our reliance
on third-party organizations; our competitive position; our
industry environment; our anticipated financial and operating
results, including anticipated sources of revenues; our assumptions
regarding the size of the available market, benefits of our
products, product pricing, and timing of product launches;
management's expectation with respect to future acquisitions;
statements regarding our goals, intentions, plans, and
expectations, including the introduction of new products and
markets; our cash needs and financing plans; and the long-term
value of Bitcoin. There are a number of factors that
could cause actual events to differ materially from those indicated
by such forward-looking statements. You should not place reliance
on these forward-looking statements, which include words such as
"could," "believe," "anticipate," "intend," "estimate," "expect,"
"may," "continue," "predict," "potential," "project" or similar
terms, variations of such terms, or the negative of those terms.
Although the Company believes that the expectations reflected in
the forward-looking statements are reasonable, the Company cannot
guarantee such outcomes. Hoth may not realize its expectations, and
its beliefs may not prove correct.
Actual results may differ materially from those indicated by these forward-looking statements as a result of
various important factors, including, without limitation,
market conditions, risks inherent with investing in
Bitcoin, including Bitcoin's volatility
and risk of implementing a new Bitcoin treasury
strategy, and the factors described in the
section titled "Risk Factors" in Hoth's most recent Annual Report
on Form 10-Kas amended or supplemented by Hoth's other filings made
with the U. S. Securities and Exchange Commission. All such
statements speak only as of the date made. Consequently,
forward-looking statements should be regarded solely as Hoth's
current plans, estimates, and beliefs. Investors should not place
undue reliance on forward-looking statements. Hoth cannot guarantee
future results, events, levels of activity, performance, or
achievements. Hoth does not undertake and specifically declines any
obligation to update, republish, or revise any forward-looking
statements to reflect new information, future events, or
circumstances or to reflect the occurrences of unanticipated
events, except as may be required by applicable law.
Investor Contact:
LR Advisors
LLC Email: investorrelations@hoththerapeutics.com
www.hoththerapeutics.com
Phone: (678) 570-6791
View original content to download
multimedia:https://www.prnewswire.com/news-releases/hoth-therapeutics-enters-partnership-with-the-department-of-veterans-affairs-to-develop-obesity-treatment-302339151.html
SOURCE Hoth Therapeutics, Inc.
